Army Medical University has identified new cyclic GMP-AMP synthase (MB21D1; cGAS)/STING pathway inhibitors potentially useful for the treatment of inflammatory disorders.
Muna Therapeutics Aps has patented new dihydropyrrolopyrimidinone compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes, obesity, metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), neurodegeneration and inflammatory bowel disease, among others.
Deep Apple Therapeutics Inc. has divulged new alkylphenyl substituted compounds acting as gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of obesity and type 2 diabetes.
Norroy Bioscience Co. Ltd. has prepared and tested peptide-drug conjugates comprising a fibroblast activation protein α (FAP)-targeting moiety linked to a radionuclide-labeled metal chelating agent for use as positron emission tomography (PET) imaging agents in the diagnosis and/or treatment of cancer.
A University of California patent describes new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1), DNA repair and serine/threonine-protein kinase ATR inhibitors potentially useful for the treatment of cancer.
Synnovation Therapeutics Inc. has discovered new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligases binding moiety coupled to nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2)-targeting moiety potentially useful for the treatment of cancer.
RSS